AUS
NZ
UK
CA
USA
IND
Health
Perrigo Receives Positive Rating from Canaccord Genuity Group
September 30, 2024 10:20 AM PDT| By Team Kalkine MediaHeadlines,Several analysts have updated their perspectives on Perrigo, reflecting varied outlooks.,Canaccord Genuity Group recently assigned a favorable rating, while others provided a more cautious outlook.,Perrigo's recent stock performance has bee...
These Pharma Giants Gain Momentum in Obesity and Diabetes Treatments
September 30, 2024 09:28 AM PDT| By Team Kalkine MediaHighlights,The GLP-1 market for obesity and diabetes treatments is gaining momentum, with Novo Nordisk and Eli Lilly leading the space.,Citi experts highlight increased prescriptions for obesity drugs like Wegovy and diabetes treatments such as Ozemp...
Citi Highlights Strong Demand Growth for Wegovy and Ozempic
September 30, 2024 08:35 AM PDT| By Team Kalkine MediaHighlights,Significant Prescription Increases,: Citi reports a 244% rise in prescriptions for obesity drugs and an 18% increase for diabetes medications.,Strong Sales Forecasts,: Estimated sales for Novo Nordisk and Eli Lilly in diabetes are projecte...
NanoViricides Prepares for Phase II Trials of Antiviral NV-387
September 30, 2024 05:52 AM PDT| By Team Kalkine MediaHighlights:,NV-387, a broad-spectrum antiviral, progresses to Phase II clinical trials targeting multiple viral infections.,Demonstrated superior efficacy in preclinical studies compared to existing antivirals, including Tamiflu and Xofluza.,Ongoing...
Genflow Biosciences Reports Significant Progress in Interim Results
September 30, 2024 05:17 AM PDT| By Team Kalkine MediaHighlights,Advancements in Longevity Treatments,: Genflow Biosciences has made notable progress in developing therapies for age-related diseases, specifically Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Werner Syndrome.,Regulatory Eng...
Chill Brands Group Shifts Focus to Viable Nicotine-Free Vapour Products
September 30, 2024 04:57 AM PDT| By Team Kalkine MediaHighlights,Chill Brands Group PLC is advancing plans for an audit review and new product launches, following secured banking provisions.,The reinstatement of CEO Callum Sommerton has provided clarity as the company navigates past challenges, includin...
Why is Viking Therapeutics (NASDAQ:VKTX) gaining limelight recently?
September 30, 2024 12:33 AM PDT| By Team Kalkine MediaViking Therapeutics (NASDAQ:VKTX), a clinical-stage biopharmaceutical company, is making significant strides in the development of a weight-loss drug that could shake up the highly competitive obesity medication market. While the company has multiple...
Stryker Corporation to Issue Dividend Payment
September 29, 2024 09:09 AM PDT| By Team Kalkine MediaHeadlines,Stryker Corporation is set to distribute a dividend to its shareholders at the end of October.,The dividend payment aligns with the company's strategy of providing consistent returns.,Despite the payout, the yield remains relatively modest...
Doximity's Capital Initiatives Signal Long-Term Growth
September 29, 2024 08:24 AM PDT| By Team Kalkine MediaHeadlines,Doximity's capital strategy suggests promising growth, highlighting its ability to reinvest profits effectively.,Return on Capital Employed (ROCE) reflects strong efficiency in Doximity's use of its capital.,Doximity’s ongoing reinvestment...
Pfizer Sees a Modest Increase in Trading Activity
September 28, 2024 12:15 AM PDT| By Team Kalkine MediaHeadlines,Pfizer's stock price saw a slight uptick in Friday's trading session.,Recent analyst ratings suggest mixed views on Pfizer, with some upgrades and price target adjustments.,Trading volume for Pfizer decreased significantly compared to its a...
New Era in Schizophrenia Care with Bristol Myers Squibb's COBENFY Approval
September 27, 2024 12:22 PM PDT| By Team Kalkine MediaHighlights,Bristol Myers Squibb's shares rose following the FDA's approval of COBENFY, the first new schizophrenia treatment in decades.,The medication, a twice-daily pill, targets specific brain receptors and aims to reduce symptoms significantly.,T...
Dynamic Forces Fueling Advancement in the Healthcare Sector
September 27, 2024 11:17 AM PDT| By Team Kalkine MediaHighlights,The Materials sector has shown strong performance recently, prompting interest in high-growth technology stocks for potential capital appreciation.,Alvotech is advancing in the biotechnology field with plans to expand its biosimilar offeri...
SpringWorks Therapeutics Navigates Challenges Amid Revenue Growth
September 27, 2024 11:15 AM PDT| By Team Kalkine MediaHighlights,SpringWorks Therapeutics has faced a recent decline in share price, contrasting with its significant appreciation over the past five years.,Despite reporting a loss recently, the company has demonstrated strong revenue growth, outpacing ty...
PureTech Health Celebrates FDA Approval of Cobenfy: A Milestone in Schizophrenia Treatment
September 27, 2024 07:18 AM PDT| By Team Kalkine MediaPureTech Health plc (Nasdaq: PRTC, LSE: PRTC) has achieved a significant milestone with the FDA's recent approval of Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in adults. This groundbreaking approval not only signif...
Tonix Pharmaceuticals Secures New Patent for Zembrace® SymTouch® in Migraine Treatment
September 27, 2024 07:05 AM PDT| By Team Kalkine MediaTonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company, recently announced a significant milestone in its mission to combat migraine disorders. On September 24, 2024, the United States Patent and Trademark Of...
Dupixent® Gains NMPA Approval for COPD Treatment in China: A New Hope for Patients
September 27, 2024 06:56 AM PDT| By Team Kalkine MediaThe National Medical Products Administration (NMPA) in China has granted approval for Dupixent® (dupilumab) as an add-on maintenance treatment for adults suffering from uncontrolled chronic obstructive pulmonary disease (COPD) characterized by elevat...
Immunic Develops Pipeline of Oral Therapies for Chronic Inflammatory and Autoimmune Diseases
September 27, 2024 05:50 AM PDT| By Team Kalkine MediaHighlights,Immunic Inc,(NASDAQ:IMUX),is advancing its lead asset, vidofludimus calcium, currently in Phase 3 trials for multiple sclerosis, with promising data presented at the ECTRIMS Congress.,The drug has shown potential to reduce neurofilament li...
Hemogenyx Pharmaceuticals Ready to Commence Phase I Trial
September 27, 2024 03:35 AM PDT| By Team Kalkine MediaHighlights,Hemogenyx Pharmaceuticals is nearing the launch of a phase I trial for HEMO-CAR-T, a treatment for acute myeloid leukaemia (AML), at the MD Anderson Center in Texas.,The company is also advancing its CBR platform and CDX program, targeting...
Molina Healthcare Achieves Impressive Shareholder Growth
September 26, 2024 02:00 PM PDT| By Team Kalkine MediaHeadlines,Molina Healthcare has delivered remarkable shareholder returns, with a significant increase in stock value over the last five years.,The company has experienced consistent earnings growth, contributing to positive market perceptions.,Invest...
Pfizer Experiences Slight Decline in Trading
September 26, 2024 01:31 PM PDT| By Team Kalkine MediaHeadlines,Pfizer Inc. experienced a modest decline in stock price, trading at approximately $28.76.,Several brokerages have adjusted their target prices, with a mix of ratings reflecting varied perspectives on the stock’s performance.,Analyst opinion...
